For adult patients with moderate to severe chronic plaque psoriasis (Ps)
REVEAL was a 52-week randomized, double-blind, placebo-controlled trial of 1212 adult patients with moderate to severe chronic plaque psoriasis. In Period C, patients who maintained at least a PASI 75 response at week 33 and were originally randomized to HUMIRA 40 mg EOW in Period A were re-randomized to receive HUMIRA 40 mg or placebo EOW for an additional 19 weeks. Proportion of patients losing an adequate response after week 33 and on or before week 52 was also studied.1,2
*PASI 75 represents a ≥75% improvement in skin clearance from baseline.
†PASI 90 represents a ≥90% improvement in skin clearance from baseline.
‡PASI 100 represents a 100% improvement in skin clearance from baseline.
§PGA of clear defined as no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red coloration. Minimal defined as possible but difficult to ascertain whether there is slight elevation of plaque above normal skin, plus or minus surface dryness with some white coloration, plus or minus up to red coloration.
BSA=body surface area; EOW=every other week; OLE=open-label extension; PASI=Psoriasis Area and Severity Index; PGA=physician’s global assessment